Michael Sheppard

41 - 50 out of 101Page size: 10
Sort by: Title

Publications

  1. Published

    NIS gene expression is a potential prognostic indicator for thyroid cancer and is inhibited by PTTG

    Kristien Boelaert, Lesley Tannahill, Margaret Eggo, Neil Gittoes, Michael Sheppard, Jayne Franklyn & Christopher McCabe, 1 Jan 2003, p. 28. 1 p.

    Research output: Contribution to conference (unpublished) › Abstract

  2. Published

    Mortality in elderly patients with subclinical hyperthyroidism

    Jim Parle, Michael Sheppard & Jayne Franklyn, 2 Mar 2002, In: Lancet. 359, 9308, p. 799-799 1 p.

    Research output: Contribution to journal › Article

  3. Published

    Mortality in Patients with Pituitary Disease

    Mark Sherlock, John Ayuk, Jeremy Tomlinson, Andrew Toogood, Aurora Aragon Alonso, Michael Sheppard, Andrew Bates & Paul Stewart, 1 Jun 2010, In: Endocrine Reviews. 31, 3, p. 301-342 42 p.

    Research output: Contribution to journal › Review article

  4. Published

    Monitoring disease activity using growth hormone and insulin like growth factor-I in the follow up of 501 patients with acromegaly.

    Mark Sherlock, Aurora Aragon Alonso, Raoul Reulen, John Ayuk, Michael Sheppard, Andrew Bates & Paul Stewart, 27 Oct 2008, In: Clinical Endocrinology.

    Research output: Contribution to journal › Article

  5. Published

    Modulation of 11beta-hydroxysteroid dehydrogenase by pro-inflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation

    Mark Cooper, Iwona Bujalska, Elizabeth Rabbitt, Elizabeth Walker, Rosemary Bland, Michael Sheppard, Martin Hewison & Paul Stewart, 1 Jun 2001, In: Journal of Bone and Mineral Research. 16, 6, p. 1037-1044 8 p.

    Research output: Contribution to journal › Article

  6. Published

    Medical therapy in acromegaly.

    Mark Sherlock & Michael Sheppard, 1 May 2011, In: Nature Reviews Endocrinology. 7, 5, p. 291-300 10 p.

    Research output: Contribution to journal › Article

  7. Published

    Medical Therapy in Patients with Acromegaly: Predictors of Response and Comparison of Efficacy of Dopamine Agonists and Somatostatin Analogues

    Mark Sherlock, Aurora Aragon Alonso, Raoul Reulen, John Ayuk, Michael Sheppard, Andrew Bates & Paul Stewart, 1 Apr 2009, In: Journal of Clinical Endocrinology and Metabolism. 94, 4, p. 1255-1263 9 p.

    Research output: Contribution to journal › Article

  8. Published

    Management of acromegaly in Latin America: expert panel recommendations

    Michael Sheppard, 1 Jun 2010, In: Pituitary. 13, 2, p. 168-175 8 p.

    Research output: Contribution to journal › Article

  9. Published

    Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly

    John Ayuk, Paul Stewart & Michael Sheppard, 1 Sep 2002, In: Journal of Clinical Endocrinology and Metabolism. 87, 9, p. 4142-4146 5 p.

    Research output: Contribution to journal › Article

  10. Published

    Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles

    Michael Sheppard, 1 Jul 2005, In: Journal of Clinical Pharmacology. 45(7), p. 836-844 9 p.

    Research output: Contribution to journal › Article

Previous 1 2 3 4 5 6 7 8 ...11 Next